{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:22:34Z","timestamp":1775550154688,"version":"3.50.1"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic myelogenous leukemia (CML) is the most common myeloproliferative disease. Protein tyrosine phosphatase receptor type \u03b3 (PTPRG) is a tumor suppressor gene and a myeloid cell marker expressed by CD34+ cells. Downregulation of PTPRG increases colony formation in the PTPRG-positive megakaryocytic cell lines MEG-01 and LAMA-84 but has no effect in the PTPRG-negative cell lines K562 and KYO-1. Its overexpression has an oncosuppressive effect in all these cell lines and is associated with myeloid differentiation and inhibition of BCR\/ABL-dependent signaling. The intracellular domain of PTPRG directly interacts with BCR\/ABL and CRKL, but not with signal transducers and activators of transcription 5. PTPRG is downregulated at the mRNA and protein levels in leukocytes of CML patients in both peripheral blood and bone marrow, including CD34+ cells, and is reexpressed following molecular remission of disease. Reexpression was associated with a loss of methylation of a CpG island of PTPRG promoter occurring in 55% of the patients analyzed. In K562 cell line, the DNA hypomethylating agent 5-aza-2\u2032-deoxycytidine induced PTPRG expression and caused an inhibition of colony formation, partially reverted by downregulation of PTPRG expression. These findings establish, for the first time, PTPRG as a tumor suppressor gene involved in the pathogenesis of CML, suggesting its use as a potential diagnostic and therapeutic target. Cancer Res; 70(21); 8896\u2013906. \u00a92010 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-0258","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T22:38:36Z","timestamp":1287527916000},"page":"8896-8906","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Protein Tyrosine Phosphatase Receptor Type \u03b3 Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia"],"prefix":"10.1158","volume":"70","author":[{"given":"Marco","family":"Della Peruta","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Moratti","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Pintani","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Vezzalini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mafficini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"},{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Grafone","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Iacobucci","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Murineddu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Vinante","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Tecchio","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Piras","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Gabbas","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Monne","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Sorio","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"},{"name":"Authors' Affiliations:\u20081Department of Pathology and Diagnostics and 2Department of Clinical and Experimental Medicine, University of Verona; 3ARC-Net Research Center, University of Verona, Policlinico G.B. Rossi, Verona, Italy; 4Institute of Hematology and Medical Oncology, \u00abLorenzo e Ariosto Seragnoli\u00bb, University of Bologna, Bologna, Italy; and 5Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, \u201cSan Francesco\u201d Hospital, ASL3, Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2010,10,31]]},"reference":[{"key":"2022061702420007200_bib1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2022061702420007200_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"2022061702420007200_bib3","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-2 region and modulate Bcr-Abl transforming activity","volume":"281","author":"Meyn","year":"2006","journal-title":"J Biol Chem"},{"key":"2022061702420007200_bib4","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/MCB.18.5.2965","article-title":"Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo","volume":"18","author":"LaMontagne","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2022061702420007200_bib5","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/sj.leu.2402214","article-title":"Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation","volume":"15","author":"Bruecher-Encke","year":"2001","journal-title":"Leukemia"},{"key":"2022061702420007200_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"2022061702420007200_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1074\/jbc.M802840200","article-title":"PTPROt inactivates the oncogenic fusion protein BCR\/ABL and suppresses transformation of K562 cells","volume":"284","author":"Motiwala","year":"2009","journal-title":"J Biol Chem"},{"key":"2022061702420007200_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrm2039","article-title":"Protein tyrosine phosphatases: from genes, to function, to disease","volume":"7","author":"Tonks","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061702420007200_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V90.1.49.49_49_57","article-title":"Receptor protein tyrosine phosphatase \u03b3, Ptp\u03b3, regulates hematopoietic differentiation","volume":"90","author":"Sorio","year":"1997","journal-title":"Blood"},{"key":"2022061702420007200_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/117727190700200036","article-title":"Protein tyrosine phosphatase \u03b3 (PTP\u03b3) is a novel leukocyte marker highly expressed by CD34+ precursors","volume":"2","author":"Mafficini","year":"2007","journal-title":"Biomarker Insights"},{"key":"2022061702420007200_bib11","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2006-05-024257","article-title":"Receptor-type protein tyrosine phosphatase \u03b3 (PTP{\u03b3}), a new identifier for myeloid dendritic cells and specialized macrophages","volume":"108","author":"Lissandrini","year":"2006","journal-title":"Blood"},{"key":"2022061702420007200_bib12","first-page":"1497","article-title":"Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP\u03b3 defines a new subfamily of receptor tyrosine phosphatases","volume":"13","author":"Barnea","year":"1993","journal-title":"Mol Cell Biol"},{"key":"2022061702420007200_bib13","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.88.11.5036","article-title":"Receptor protein-tyrosine phosphatase \u03b3 is a candidate tumor suppressor gene at human chromosome region 3p21","volume":"88","author":"LaForgia","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702420007200_bib14","first-page":"3710","article-title":"Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas","volume":"54","author":"Lubinski","year":"1994","journal-title":"Cancer Res"},{"key":"2022061702420007200_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0304-3835(98)00344-9","article-title":"Reduced expression of protein tyrosine phosphatase \u03b3 in lung and ovarian tumors","volume":"137","author":"van Niekerk","year":"1999","journal-title":"Cancer Lett"},{"key":"2022061702420007200_bib16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2559.2007.02661.x","article-title":"Expression of transmembrane protein tyrosine phosphatase \u03b3 (PTP\u03b3) in normal and neoplastic human tissues","volume":"50","author":"Vezzalini","year":"2007","journal-title":"Histopathology"},{"key":"2022061702420007200_bib17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1096096","article-title":"Mutational analysis of the tyrosine phosphatome in colorectal cancers","volume":"304","author":"Wang","year":"2004","journal-title":"Science"},{"key":"2022061702420007200_bib18","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1158\/0008-5472.CAN-06-0157","article-title":"Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas","volume":"66","author":"Furuta","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702420007200_bib19","first-page":"536","article-title":"[Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]","volume":"86","author":"Wang","year":"2006","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2022061702420007200_bib20","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1200\/JCO.2005.11.353","article-title":"Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, p73","volume":"23","author":"van Doorn","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061702420007200_bib21","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.1158\/0008-5472.CAN-08-0904","article-title":"Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma","volume":"68","author":"Cheung","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702420007200_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ijc.2910180405","article-title":"Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia","volume":"18","author":"Klein","year":"1976","journal-title":"Int J Cancer"},{"key":"2022061702420007200_bib23","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood.V66.6.1384.1384","article-title":"Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome","volume":"66","author":"Ogura","year":"1985","journal-title":"Blood"},{"key":"2022061702420007200_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0145-2126(85)90314-5","article-title":"A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis","volume":"9","author":"Ohkubo","year":"1985","journal-title":"Leuk Res"},{"key":"2022061702420007200_bib25","first-page":"822","article-title":"Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics","volume":"15","author":"Seigneurin","year":"1987","journal-title":"Exp Hematol"},{"key":"2022061702420007200_bib26","first-page":"4855","article-title":"Characterization of the receptor protein tyrosine phosphatase gene product PTP\u03b3: binding and activation by triphosphorylated nucleosides","volume":"55","author":"Sorio","year":"1995","journal-title":"Cancer Res"},{"key":"2022061702420007200_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.onc.1207235","article-title":"Function analysis of estrogenically regulated protein tyrosine phosphatase \u03b3 (PTP\u03b3) in human breast cancer cell line MCF-7","volume":"23","author":"Liu","year":"2004","journal-title":"Oncogene"},{"key":"2022061702420007200_bib28","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V95.7.2391","article-title":"Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways","volume":"95","author":"Witt","year":"2000","journal-title":"Blood"},{"key":"2022061702420007200_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1096\/fasebj.12.7.531","article-title":"Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin","volume":"12","author":"Belhacene","year":"1998","journal-title":"FASEB J"},{"key":"2022061702420007200_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/320275a0","article-title":"Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells","volume":"320","author":"Hock","year":"1986","journal-title":"Nature"},{"key":"2022061702420007200_bib31","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"2022061702420007200_bib32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1096\/fj.04-3000fje","article-title":"Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers","volume":"19","author":"Mauri","year":"2005","journal-title":"FASEB J"},{"key":"2022061702420007200_bib33","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells","volume":"84","author":"Nichols","year":"1994","journal-title":"Blood"},{"key":"2022061702420007200_bib34","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia","volume":"84","author":"ten Hoeve","year":"1994","journal-title":"Blood"},{"key":"2022061702420007200_bib35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry","volume":"20","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"key":"2022061702420007200_bib36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Horita","year":"2000","journal-title":"J Exp Med"},{"key":"2022061702420007200_bib37","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"2022061702420007200_bib38","first-page":"1724","article-title":"BCR\/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats","volume":"10","author":"Frank","year":"1996","journal-title":"Leukemia"},{"key":"2022061702420007200_bib39","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"2022061702420007200_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.anndiagpath.2006.12.002","article-title":"New insights into the pathobiology and treatment of chronic myelogenous leukemia","volume":"11","author":"Cotta","year":"2007","journal-title":"Ann Diagn Pathol"},{"key":"2022061702420007200_bib41","doi-asserted-by":"crossref","first-page":"27413","DOI":"10.1074\/jbc.M304575200","article-title":"Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway","volume":"278","author":"Chien","year":"2003","journal-title":"J Biol Chem"},{"key":"2022061702420007200_bib42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.exphem.2004.07.024","article-title":"A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein","volume":"32","author":"Shimizu","year":"2004","journal-title":"Exp Hematol"},{"key":"2022061702420007200_bib43","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"key":"2022061702420007200_bib44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/21\/8896\/2645595\/8896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/21\/8896\/2645595\/8896.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T06:22:50Z","timestamp":1655446970000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/70\/21\/8896\/561594\/Protein-Tyrosine-Phosphatase-Receptor-Type-Is-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,31]]},"references-count":44,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2010,10,31]]},"published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-0258","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22386608","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386605","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6501587","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386608.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386605.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6501587.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,31]]}}}